Multiple sclerosis in New Zealand
- PMID: 24503208
- DOI: 10.1016/j.jocn.2013.09.009
Multiple sclerosis in New Zealand
Abstract
New Zealand (NZ) is a high risk country for multiple sclerosis (MS) with an overall age and sex standardised prevalence of 73.1 per 100,000 population. The age and sex standardised prevalence within the Māori population is substantially lower at 24.2 per 100,000 population. A latitudinal gradient exists with MS prevalence increasing threefold from the North (37°S) to the South (48°S) of NZ. Over 1600 (56.8%) persons with MS experience moderate to severe disability. Despite the high prevalence of MS and the significant degree of disability experienced by people with MS, the availability and prescribing guidelines for MS disease modifying treatments are more restrictive in NZ than in other developed nations.
Keywords: Disability; Genetic; Incidence; Latitude gradient; Multiple sclerosis; Prevalence; Socioeconomic impact.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
The increasing prevalence of multiple sclerosis in New Zealand.Neuroepidemiology. 2014;42(3):154-60. doi: 10.1159/000358174. Epub 2014 Feb 20. Neuroepidemiology. 2014. PMID: 24556851 Review.
-
Multiple sclerosis is more prevalent in northern New Zealand than previously reported.Intern Med J. 2003 Mar;33(3):79-83. doi: 10.1046/j.1445-5994.2003.00332.x. Intern Med J. 2003. PMID: 12603579
-
MS prevalence in New Zealand, an ethnically and latitudinally diverse country.Mult Scler. 2010 Dec;16(12):1422-31. doi: 10.1177/1352458510379614. Epub 2010 Sep 2. Mult Scler. 2010. PMID: 20813774
-
The latitude gradient for multiple sclerosis prevalence is established in the early life course.Brain. 2021 Aug 17;144(7):2038-2046. doi: 10.1093/brain/awab104. Brain. 2021. PMID: 33704407
-
The changing demographic pattern of multiple sclerosis epidemiology.Lancet Neurol. 2010 May;9(5):520-32. doi: 10.1016/S1474-4422(10)70064-8. Lancet Neurol. 2010. PMID: 20398859 Review.
Cited by
-
Disease-Modifying Therapies in Multiple Sclerosis: Overview and Treatment Considerations.Fed Pract. 2016 Jun;33(6):28-34. Fed Pract. 2016. PMID: 30766181 Free PMC article.
-
Evaluation of a Fatigue Self-Management Program for People with Multiple Sclerosis.Int J MS Care. 2016 May-Jun;18(3):116-21. doi: 10.7224/1537-2073.2015-019. Int J MS Care. 2016. PMID: 27252598 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical